Summary
All-trans-retinoic acid, hexamethylene bisacetamide and 5-azacytidine are inducers of granulocytic differentiation of HL-60 human myeloid leukaemic cells, which eventually leads to inhibition of cell proliferation. The effect of graded concentrations of all-trans-retinoic acid (RA) (1 nM-1 ΜM), hexamethylene bisacetamide (HMBA) (0.5–4 mM) and/or 5-azacytidine (5azaC) (1 nM-1 mM), alone and in combination with each other on colony formation and growth of HL-60 cells was studied in agar capillary clonogenic micro assays in order to identify new potential therapeutic regimens for elderly patients with acute myeloid leukaemia. ED90 concentrations, inducing 90% inhibition of colony formation for RA, HMBA and 5azaC, were 128 nM, 2.7 mM and 40 ΜM, respectively. The drug interactions between these differentiating agents were analysed by Berenbaum's general algebraic solution. The combinations: RA + HMBA, 5azaC + HMBA and RA + 5azaC were significantly synergistic in inhibiting HL-60 colony formation. Their interaction indices were 0.62, 0.83, and 0.97, respectively, at a specific effect level of 15%. The addition of 1 mM HMBA to 100 nM 5azaC- and 1 nM RA-treated cultures significantly increased the colony-formation inhibition from only 2.6% and 7.0% to 46.4%, and 43.1 %, respectively. Also, HMBA showed marked synergism with RA and 5azaC in inhibiting colony growth. The interaction indices (I) of HMBA + RA and HMBA + 5azaC were 0.013 and 0.009, respectively, at the same specific level of 15%. Moreover, the triple combination of RA + HMBA + 5azaC showed synergism in inhibiting both the colony formation (I=0.7) and colony growth (I=0.4) at the same specific level of 15%. Since RA, HMBA and 5azaC were effective when administered alone in phase I clinical trials of myeloid leukaemic patients, their synergistic combinations could provide shorter and less toxic courses of treatment in elderly myeloid leukaemic patients.I is < 1, =1 or > 1 in synergistic, additive or antagonistic interactions, respectively.
Similar content being viewed by others
Abbreviations
- AML:
-
acute myeloid leukaemia
- 5-azaC:
-
5-azacytidine
- HMBA:
-
hexamethylene bisacetamide
- RA:
-
all-trans-retinoic acid
References
Asano Y, Okamura S, Shibuya T, Morioka E, Hirota Y, Niho Y (1989) Development of drug resistance in cultured clonogenic leukaemic blast cells during the clinical course of myeloblastic leukaemia. Oncology 46:339–342
Berenbaum MC (1989) What is synergy? Pharmacol Rev 41:93–141
Breitman TR, He R (1990) Combinations of retinoic acid with either sodium butyrate, dimethylsulphoxide or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukaemia cell line HL-60. Cancer Res 50:6268–6273
Breitman TR, Collins SJ, Keene BR (1981) Terminal differentiation of human promyelocytic leukaemia cells in primary culture in response to retinoic acid. Blood 57:1000–1004
Castaigne S, Chomienne C, Ballerini P, Huang ME, Daniel MT, Berger R, Miclea JM, Degos L (1989) All-trans retinoic acid: a novel differentiation therapy for acute promyelocytic leukaemia. Blood 74[Suppl 1]:117a, 434
Christman JK, Mendelsohn N, Herzog D, Schneiderman N (1983) Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukaemia cells HL-60. Cancer Res 43:763–767
Collins SJ, Bodner A, Ting R, Gallo RC (1980) Induction of both morphological and functional differentiation of human HL-60 promyelocytic leukaemia cells by compounds which induce the differentiation of murine leukaemia cells. Int J Cancer 25:213–218
Copplestone JA, Prentice AG (1988) Acute myeloblastic leukaemia in the elderly. Leuk Res 12:617–625
Curtis JE, Messner HA, Minden MD, Tritchler DL, McCulloch EA (1989) Improved maintenance therapy for acute myelogenous leukaemia (AML) using retinoic acid containing regimen. Proc Am Assoc Cancer Res Annu Meet 30:268, 1006
Egorin MJ (1988) Clinical trials of polar compounds. In: Waxman S, Rossi GB, Takaku F (eds) The status of differentiation therapy of cancer. Raven, New York, pp 389–404
Hassan HT (1988a) Differentiation induction therapy: an alternative for the treatment of elderly patients with acute myelogenous leukaemias. J Clin Exp Gerontol 10:63–73
Hassan HT (1988b) Differentiation inducers of human myeloid leukaemia cell lines. Folia Haematol (Leipz) 115:887–896
Hassan HT, Rees JKH (1988) Retinoic acid alone and in combination with cytosine arabinoside induces differentiation of myelomonocytic and monoblastic leukaemic cells. Haematol Oncol 6:39–45
Hassan HT, Rees JKH (1989a) Differentiation induction therapy of myelodysplastic syndromes. Leuk Res 13:633–637
Hassan HT, Rees JKH (1989b) Triple combination of retinoic acid + aclacinomycin A + dimethylformamide induces differentiation of human acute myeloid leukaemic blasts in primary culture. Anticancer Res 9:647–652
Hassan HT, Rees JKH (1990a) Effect of AML serum on normal human myeloid differentiation and hexamethylene bisacetamideinduced granulocytic differentiation of the human HL-60 promyelocytic leukaemic cell line. Folia Haematol (Leipz) 117:151–159
Hassan HT, Rees JKH (1990b) Myeloid leukaemogenesis and its reversal by combined differentiation induction therapy: a complementary model. Med Sci Res 18:47–52
Hassan HT, Pearson EC, Rees JKH (1990) Retinoic acid induces granulocytic differentiation of myeloid progenitors in congenital agranulocytosis bone marrow cells. Cell Biol Int Rep 14:247–254
Karon M, Sieger L, Leimbrock S, Finkelstein JZ, Nesbit ME, Swaney J (1973) 5-azacytidine: a new active agent for the treatment of acute leukaemia. Blood 42:359–362
Kasukabe T, Honma Y, Hozumi M, Suda T, Nishii Y (1987) Control of proliferating potential of myeloid leukaemic cells during long term treatment with vitamin D3 analogues and other differentiating agents in combination with antileukaemic drugs; in vitro and in vivo studies. Cancer Res 47:567–572
Langdon SP, Hickman JA, Gescher A, Stevens MFG, Chubb D, Viskers LM (1985) N-Methylformamide: a potential candidate for combination therapy. Eur J Cancer Clinical Oncol 21:745–752
Lie SO, Wathne K, Peterson LB, Slordehl SH, Norum KR (1988) High dose retinol in children with AML in remission. Eur J Haematol 40:460–465
Lübbert M, Koeffler HP (1988) Myeloid cell lines: tools for studying the differentiation of normal and abnormal haemopoietic cells. Blood Rev 2:121–133
Maurer HR, Echarti C (1990) Clonogenic assays for haemopoietic and tumour cells using agar containing capillaries. In: Pollard JW, Walker JM (eds) Methods in molecular biology, vol 5. Animal cell culture. Humana, New York, pp 379–394
Meng-er H, Yu-Chen Y, Shu-rong C, Jin-ren C, Jia-Xiang L, Lin Z, Long-jun G, Zhen-yi W (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukaemia. Blood 72:567–572
Rees JKH (1989) Chemotherapy of acute myeloid leukaemia in UK: past, present and future. Bone Marrow Transplant 4 [Suppl 1]:110–113
Sachs L (1978) The differentiation of myeloid leukaemia cells: new possibilities for therapy. Br J Haematol 40:509–517
Saiki JH, McCredie KB, Vietti TJ, Helwett JS, Morrison FS, Costanzi JJ, Stuckey WJ, Whitecar J, Hoogstraten B (1978) 5-Azacytidine in acute leukaemia. Cancer 42:2111–2115
Silverman LR, Richardson E, Ohnuma T, Cuttner J, Holland JF (1988) 5-Azacytidine and cytosine arabinoside in combination potentiate the induction of differentiation of HL-60 promyelocytic leukaemia cells. Proc Am Assoc Cancer Res Annu Meet 29:35,139A
Wijermans PW, Rebel VI, Ossenkoppele GJ, Huijgens PC, Langenhuijsen MMAC (1989) Combined procoagulant activity and proteolytic activity of acute promyelocytic leukaemia cells: reversal of the bleeding disorder by cell differentiation. Blood 73:800–805
Wu X, Shao G, Chen S, Wang X, Wang ZY (1989) Studies on the relationship between protein kinase C and differentiation of human promyelocytic leukaemia cells induced by retinoic acid. Leuk Res 13:869–874
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hassan, H.T., Veit, A. & Maurer, H.R. Synergistic interactions between differentiation-inducing agents in inhibiting the proliferation of HL-60 human myeloid leukaemia cells in clonogenic micro assays. J Cancer Res Clin Oncol 117, 227–231 (1991). https://doi.org/10.1007/BF01625429
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01625429